This CPB has been revised to state that or ocrelizumab and hyaluronidase-ocsq (Ocrevus Zunovo) is considered medically necessary for the treatment of relapsing forms of multiple sclerosis (MS), clinically isolated syndrome, and primary progressive MS when criteria are met. This CPB has been revised to state that the Multiple Sclerosis Disease Activity (MSDA) Test is considered experimental, investigational, or unproven for monitoring disease progression. This CPB has been updated to add the following: (i) precertification requirement for Ocrevus Zunovo; (ii) Site of Care Utilization Management requirement for Ocrevus Zunovo; and (iii) designate Ocrevus Zunovo as a more costly brand of targeted immune modulator for treatment of relapsing forms of multiple sclerosis.